Table 3.
Distribution of main diagnosis groups based on their biotechnological or small-molecule drug status.
| Main diagnosis group | Biotechnological drugs | Small-molecule drugs | ||
|---|---|---|---|---|
| n (%) | The most frequent drug, (%*) | n (%) | The most frequent drug, (%*) | |
| Certain infectious and parasitic diseases | 12 (0.7) | Interferon beta-1a, (41.7) | 85 (3.0) | Valganciclovir, (44.7) |
| Neoplasms | 208 (12.2) | Bevacizumab, (21.6) | 579 (20.7) | Isotretinoin, (11.9) |
| Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | 350 (20.5) | Eculizumab, (50.0) | 222 (7.9) | Eltrombopag, (26.6) |
| Endocrine, nutritional and metabolic diseases | 578 (33.9) | Canakinumab, (31.7) | 761 (27.2) | Sapropterin, (25.1) |
| Diseases of the nervous system | 34 (2.0) | Rituximab, (41.2) | 205 (7.3) | Ataluren, (22.0) |
| Diseases of the eye and adnexa | 2 (0.1) | Rituximab, (100.0) | 14 (0.5) | Idebenone, (35.7) |
| Diseases of the circulatory system | 6 (0.4) | Dornase alfa, (50,0) | 431 (15.4) | Iloprost, (32.7) |
| Diseases of the respiratory system | 5 (0.3) | Dornase alfa, (40,0) | 2 (0.1) | Pamidronic acid, (50.0) |
| Diseases of the digestive system | 14 (0.8) | Denosumab, (50.0) | 22 (0.8) | Mycophenolate, (36.4) |
| Diseases of the skin and subcutaneous tissue | 5 (0.3) | Intravenous immunoglobulin, (20.0) | 9 (0.3) | Flutamide, (44.4) |
| Diseases of the musculoskeletal system and connective tissue | 330 (19.4) | Adalimumab, (29.7) | 89 (3.2) | Mycophenolate, (69.7) |
| Diseases of the genitourinary system | 127 (7.5) | Rituximab, (84.3) | 249 (8.9) | Mycophenolate, (56.6) |
| Certain conditions originating in the perinatal period | 1 (0.1) | Factor VIII inhibitor bypassing activity, (100.0) | 54 (1.9) | Calcium folinate, (29.6) |
| Congenital malformations, deformations, and chromosomal abnormalities | 32 (1.9) | Somatropin, (96.9) | 75 (2.7) | Sirolimus, (36.0) |
| Total | 1704 (100.0) | Canakinumab, (15.3) | 2797 (100.0) | Mycophenolate, (9.8) |
*Percentage of drugs that are used in the diagnosis group column below.